Related Experiment Video
Updated: Jul 15, 2025

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece
Nikolaos Nomikos1, Christos Eleftheriou2, Kostas Athanasakis1
1Laboratory for Health Technology Assessment, Department of Public Health Policy, School of Public Health, University of West Attica, 11521 Athens, Greece.
Abstract:
This study aimed to assess the cost-effectiveness of abobotulinumtoxinA (aboBoNT-A) plus Best Supportive Care (BSC) compared with BSC alone for managing limb spasticity in adult patients in Greece, as well as to conduct a budget impact analysis of the introduction of aboBoNT-A in the Greek healthcare system compared to onabotulinumtoxinA (onaBoNT-A). Clinical studies were utilized to extract data on drug efficacy and patients' utility, while cost data were collected from Greek sources. The results of the study showed that aboBoNT-A plus BSC was a cost-effective treatment option for both upper and lower limb spasticity in adult patients compared to BSC. Additionally, introducing aboBoNT-A into the Greek healthcare system resulted in cost savings in pharmaceutical spending over a 5-year period. The findings suggest that incorporating aboBoNT-A into the Greek healthcare system could improve patient access to treatment and healthcare resource efficiency, as it is a more economical option compared to onaBoNT-A.
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses
Depolarizing Blockers: Pharmocokinetics
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...

